Biotech, spinout locked in battle over royalty from blockbuster GSK lung drugs
The biotech company wants the 85% of royalties it says it is due from a COPD and asthma drug from GSK. Its onetime spinout, now swayed by an activist investor, instead wants to invest that money during a hot biotech market.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Asthma | Biotechnology | Chronic Obstructive Pulmonary | Health Management